Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth K Tanabe

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
The Oncologist|August 7, 2015
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaLipika Goyal, Aparna Govindan, Rahul A Sheth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2020
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRIDerek J Erstad, Mozhdeh Sojoodi, Martin S Taylor, et al.
Theranostics|September 30, 2024
Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studiesShadi A Esfahani, Hua Ma, Shriya Krishna, et al.
Annals of Surgery|February 21, 2022
Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Versus the Standard of Care Imaging in the Diagnosis of Peritoneal CarcinomatosisFelipe S Furtado, Mark Z Wu, Shadi A Esfahani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 7, 2012
MelanomaDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of the National Cancer Institute|September 28, 2017
Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor GenotypeTheodore S Hong, Jennifer Y Wo, Darrell R Borger, et al.
JCI Insight|July 8, 2022
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivationEmilie Crouchet, Shen Li, Mozhdeh Sojoodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaTheodore S Hong, Jennifer Y Wo, Beow Y Yeap, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 10, 2019
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinomaCristina Ferrone, Lipika Goyal, Motaz Qadan, et al.
Gut|March 29, 2020
Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinomaFrank Jühling, Nourdine Hamdane, Emilie Crouchet, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
The Oncologist|August 7, 2015
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaLipika Goyal, Aparna Govindan, Rahul A Sheth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2020
Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRIDerek J Erstad, Mozhdeh Sojoodi, Martin S Taylor, et al.
Theranostics|September 30, 2024
Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studiesShadi A Esfahani, Hua Ma, Shriya Krishna, et al.
Annals of Surgery|February 21, 2022
Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Versus the Standard of Care Imaging in the Diagnosis of Peritoneal CarcinomatosisFelipe S Furtado, Mark Z Wu, Shadi A Esfahani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 7, 2012
MelanomaDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Journal of the National Cancer Institute|September 28, 2017
Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor GenotypeTheodore S Hong, Jennifer Y Wo, Darrell R Borger, et al.
JCI Insight|July 8, 2022
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivationEmilie Crouchet, Shen Li, Mozhdeh Sojoodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaTheodore S Hong, Jennifer Y Wo, Beow Y Yeap, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 10, 2019
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinomaCristina Ferrone, Lipika Goyal, Motaz Qadan, et al.
Gut|March 29, 2020
Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinomaFrank Jühling, Nourdine Hamdane, Emilie Crouchet, et al.
Pageof 21